Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Trial to Determine the Safety and Immunogenicity of Healthy Candidate MERS-CoV Vaccine (MERS002)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04170829
Recruitment Status : Recruiting
First Posted : November 20, 2019
Last Update Posted : February 20, 2020
Sponsor:
Collaborator:
University of Oxford
Information provided by (Responsible Party):
King Abdullah International Medical Research Center

Brief Summary:
A phase Ib study to determine the safety and immunogenicity of the candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) vaccine ChAdOx1 MERS in healthy adult Middle Eastern volunteers

Condition or disease Intervention/treatment Phase
Middle East Respiratory Syndrome Coronavirus Biological: ChAdOx1 MERS Phase 1

Detailed Description:

This is an open-label, dose escalation phase 1b trial to assess the safety and immunogenicity of the candidate ChAdOx1 MERS vaccine in healthy Middle Eastern adult volunteers aged 18-50. The first-in-human trial is now being conducted in Oxford in UK healthy adult volunteers. The vaccine will be administered intramuscularly.

Volunteers will be recruited and vaccinated at the King Abdulaziz Medical City, M-NGHA, Riyadh. There will be 3 study groups and a total of 24 volunteers will be enrolled. Staggered enrolment will apply for the first three volunteers within each group. Volunteers will be first recruited into Group 1 and subsequently into Groups 2 and 3 following interim clinical safety reviews. Volunteers will be allocated to a study group by selecting eligible volunteers for enrolment in the order in which they were deemed eligible, following screening.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Open-labelled, non-randomised, dose escalation, extension for a first-in-human, single centre, phase Ib clinical trial
Masking: None (Open Label)
Masking Description: Open-labelled, non-randomised, dose escalation, extension for a first-in-human, single centre, phase Ib clinical trial
Primary Purpose: Prevention
Official Title: A Phase Ib Study to Determine the Safety and Immunogenicity of the Candidate Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Vaccine ChAdOx1 MERS in Healthy Adult Middle Eastern Volunteers
Actual Study Start Date : December 17, 2019
Estimated Primary Completion Date : September 1, 2020
Estimated Study Completion Date : January 1, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group 1 (n=6)
will be administered ChAdOx1 MERS: 5 x 109 vp ChAdOx1 MERS
Biological: ChAdOx1 MERS
a replication-deficient simian adenoviral vector expressing the spike (S) protein of MERS Coronavirus.

Experimental: Group 2 (n=9)
will be administered ChAdOx1 MERS: 2.5 x 1010 vp ChAdOx1 MERS
Biological: ChAdOx1 MERS
a replication-deficient simian adenoviral vector expressing the spike (S) protein of MERS Coronavirus.

Experimental: Group 3 (n=9)
will be administered ChAdOx1 MERS: 5 x 1010 vp ChAdOx1 MERS
Biological: ChAdOx1 MERS
a replication-deficient simian adenoviral vector expressing the spike (S) protein of MERS Coronavirus.




Primary Outcome Measures :
  1. Occurrence of solicited and unsolicited local and systemic adverse events [ Time Frame: 28 days following the vaccination ]
    The specific endpoints for safety and reactogenicity will be actively and passively collected data on adverse events. Change from baseline for safety laboratory measures will also be collected. Occurrence of serious adverse events will be collected during the whole study duration


Secondary Outcome Measures :
  1. Measures of immunogenicity to the ChAdOx1 MERS vaccine [ Time Frame: 6.5 months following completion of the vaccination regimen ]
    ELISA to quantify antibodies to MERS Spike protein antigen Ex vivo ELISpot responses to MERS Spike protein antigen



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy* ME adults aged 18 to 50 years
  2. Able and willing (in the Investigator's opinion) to comply with all study requirements
  3. Willing to allow the investigators to access the volunteer's medical history.
  4. For females only, not planning to get pregnant during the study and a negative pregnancy test on the day(s) of screening and vaccination. Effective methods of contraception must be used. See section 6.3.3
  5. Agreement to refrain from blood donation during the course of the study
  6. Provide written informed consent

Exclusion Criteria:

  1. Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period
  2. Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data.
  3. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
  4. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed)
  5. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
  6. Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema.
  7. Any history of anaphylaxis in relation to vaccination
  8. Pregnancy, lactation or willingness/intention to become pregnant during the study
  9. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)
  10. History of serious psychiatric condition likely to affect participation in the study
  11. Bleeding disorder (eg. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture
  12. Any other serious chronic illness requiring hospital specialist supervision
  13. Suspected or known current alcohol use.
  14. Suspected or known drug abuse in the 5 years preceding enrolment
  15. Seropositive for hepatitis B surface antigen (HBsAg)
  16. Seropositive for hepatitis C virus (antibodies to HCV)
  17. Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis
  18. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data
  19. History of exposure to MERS-CoV *
  20. History of contact with camels. Defined as working in farms or barns; having been within 6 feet (2 meters) of a sick camel without PPE; or consumption of raw milk or uncooked meat. For this study, 30 days prior to screening will be considered.
  21. History of allergic reaction to Aminoglycoside antibiotics. *rRT-PCR testing of nasopharyngeal specimen , at the discretion of PI, may be indicated when a volunteer is suspected to be asymptomatic carrier.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04170829


Contacts
Layout table for location contacts
Contact: Majed Al Jeraisy, M.Sc. 0096611 849 4455 ext 94455 JeraisyM@NGHA.MED.SA
Contact: Naif Alharbi, PHD 0096611 849 4455 ext 94552 harbina2@ngha.med.sa

Locations
Layout table for location information
Saudi Arabia
King Abdulaziz Medical City, National Guard Health Affairs Recruiting
Riyadh, Saudi Arabia, 11426
Contact: Mohammad Bosaeed, MD    +966(11)8011111 ext 17535    dr.bosaeed@live.com   
Contact: Volunteer Coordinator    +966 50 468 6118    MERS002@ngha.med.sa   
Principal Investigator: Mohammad Bosaeed, MD         
Sponsors and Collaborators
King Abdullah International Medical Research Center
University of Oxford
Investigators
Layout table for investigator information
Principal Investigator: Mohammad Bosaeed, MD Ministry of National Guard-Health Affairs (MNGHA)

Layout table for additonal information
Responsible Party: King Abdullah International Medical Research Center
ClinicalTrials.gov Identifier: NCT04170829    
Other Study ID Numbers: CT18/004/R
MERS002 ( Other Grant/Funding Number: University of Oxford )
First Posted: November 20, 2019    Key Record Dates
Last Update Posted: February 20, 2020
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by King Abdullah International Medical Research Center:
MERS-CoV
ChAdOx1 MERS
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronavirus Infections
Syndrome
Disease
Pathologic Processes
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Virus Diseases